United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

American Assets

Agree Realty

Broadstone Net Lease

Chevron

Hess

Hess Midstream Partners

Innovative Industrial Properties

LyondellBasell Industries

Realty Income Corp

W. P. Carey

Dividend growth stocks can offer a passive way to grow your cash flow over time that can be used to pay the bills during retirement. We screen for some attractive names to consider, looking at dividend safety, growth and consistency, highlighting 5 that come with some of the highest yields. This month, we have 3 familiar names that make the screening regularly, but we also have 2 new names that we haven't touched on previously.

October's 5 Dividend Growth Stocks With 5.10%+ Yields

Franklin Resources

Crown Castle International

Healthpeak Properties Inc

Dow Inc

Ford Motor Company

KeyCorp

Altria

Simon Property Group

AT&T

Truist Financial

Verizon

Walgreens

The Standard & Poor's 500 Index was created by credit agency Standard & Poor's in 1957.

These 15 Stocks Are Among the Top Dividend Payers in the S&P 500

Abbott Labs

Johnson & Johnson

These stocks could deliver big over the long term.

3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now

Eagle Point Credit

Enterprise Products Partners

Generation Income Properties

NextEra Energy

Orchid Island Capital

Oxford Lane Capital

Prospect Capital

Ready Capital Corp

Sirius XM Holdings Inc

Presidio Property Trust

STAG Industrial

Triplepoint Venture Growth BDC

Trinity Capital

Since May 2017, any dividend-paying stock mentioned by readers is included in my reader favorite listings, highlighting potential opportunities and risks. My stock lists aim to identify promising dividend stocks, using a contrarian investing strategy, primarily for new buyers seeking high-yield opportunities. Reader feedback is crucial for correcting errors and refining strategies, including suggestions for buy-and-hold stocks and option strategies for monthly dividends.

Readers Identify 25 Ideal September Dividend Buys Out Of 39 Picks

Baby Boomers looking to put new money to work may wish to check out the broader basket of dividend stocks while interest rates are still relatively elevated.

Baby Boomers: 2 Dividend Stocks to Buy Under $30

Pfizer's high dividend yield and robust pipeline could offer significant returns for patient investors.

Why I'm Considering Leaning Heavily Into Pfizer

TXO Energy Partners LP

As we move further into October, many investors may be looking to identify certain stocks with the potential to provide additional capital appreciation upside, but also some strong dividend income.

3 Top High-Yield Dividend Stocks to Buy in October 2024

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as it faces pressure from activist hedge fund Starboard Value.

Pfizer taps Vanguard veteran for board amid fight with Starboard

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the election of Mortimer (“Tim”) J. Buckley to its Board of Directors, effective immediately, following a lengthy and comprehensive search that began in May 2024. Mr. Buckley, age 55, was also appointed to and will join the Governance and Sustainability Committee and the Audit Committee of Pfizer's Board. Following the appointment of Mr. Buckley, the Board will comprise 14 directors, 13 of whom are independent. Mr. Buckley serve.

Tim Buckley Elected to Pfizer's Board of Directors

This investor's campaign is stoking some undesirable corporate intrigue.

Pfizer Is Clashing With Its New Activist Investor. Will It Harm The Stock?

Two supercharged income stocks -- sporting yields of 5.6% and 5.8% -- have the tools and intangibles needed to catapult higher.

2 Ultra-High-Yield Dividend Stocks With Total Return Potential of Up to 92% in 12 Months, According to Select Wall Street Analysts

Arcadium Lithium PLC

Netflix

Selling the news is a common trading strategy in which traders buy a stock in anticipation of expected news, then sell once the event occurs. It's a short-term strategy based on the psychology that the unknown is frequently better or worse than the known.

These 3 Stocks Just Spiked—Buy the Rally or Sell the News?

Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be administered via a pre-filled, auto-injector pen.

Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi

Eli Lilly

These two stocks will appeal to very different types of investors at the moment.

Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?

AbbVie

Buying these stocks gives you a great chance to beat the benchmark.

Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade

e.l.f. Beauty

These businesses are trading at discounts right now.

2 Unstoppable Growth Stocks to Buy Right Now for Less than $200

News for Pfizer Stock (PFE)